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Abstract
Background: Epilepsy in the cat is a serious medical condition. To date there are no licensed treatments for feline
epilepsy and no well-controlled clinical studies on the efficacy or safety of antiepileptic drugs in cats. The aim of
this study was to collect tolerability data and first exploratory efficacy data of imepitoin in both healthy and
epileptic cats.
Results: In two tolerability studies, 30 healthy cats received imepition twice daily in doses of 0, 30, 40 or 80 mg/kg
bodyweight for 30 days. No serious adverse events were observed in any of the dose groups. In the imepitoin
treated groups, emesis was observed in some animals temporarily and intermittently mainly in the second and
third weeks of treatment.
In a small, single-arm, open label, uncontrolled clinical trial eight cats suffering from idiopathic epilepsy were
treated with imepitoin twice daily at doses of 30 mg/kg bodyweight for 30 days. Four of these cats (50%) achieved
seizure freedom for at least 8 weeks under treatment. Adverse events, mostly lethargy, decreased appetite and
emesis, were often mild and transient.
Conclusion: In summary, imepitoin was well tolerated in healthy and epileptic cats and showed in a pilot trial
indication for efficacy in treating feline epilepsy.
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Background
Epileptic seizures are the most common neurologic
problem encountered in small animal medicine [1].
When possible, the underlying cause of occurring sei-
zures is identified and treated. If the underlying cause
cannot be identified or is untreatable, treatment involves
the administration of antiepileptic drugs in an attempt
to control seizure frequency and/ or seizure severity [2].
Appropriate treatment can be especially difficult in cats
since to date there are no licensed treatments for feline
epilepsy and no well-controlled clinical studies on the
efficacy or safety of antiepileptic drugs in cats [3].
Whereas the etiology and diagnosis of epilepsy show
similarities between dogs and cats, treatment with
antiepileptic drugs (AEDs) in cats is different than in
dogs [3, 4].
Benzodiazepine-like agents act through positive allosteric
modulation of gamma-aminobutyric acidA (GABAA) recep-
tors, potentiating the inhibitory effects of GABA in indu-
cing Cl− currents, leading to hyperpolarisation of neurons
and inhibitory effects on transmission [5]. Benzodiazepines
such as diazepam or clonazepam are considered highly
efficacious in treating many forms of epilepsy. However,
these benzodiazepines act as full agonists of GABAA recep-
tors, and long-term treatment is associated with loss of
efficacy (tolerance) and development of physical depend-
ence in both dogs and humans [6, 7].
In cats, oral diazepam has a longer elimination half-life
(15–20 h) than in dogs (3–4 h) and cats do not develop
functional tolerance to the drug in contrast to other
species, including rat, mouse, dog and human [8, 9].
Along with non-fatal adverse events like sedation, polyuria
and polydipsia, diazepam has been linked to potentially
fatal idiosyncratic hepatotoxicosis, hepatic necrosis and
liver failure in cats [10]. Consequently, diazepam is often
not considered a viable maintenance oral anticonvulsant
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option for cats [4, 11]. For the same reason other benzodi-
azepines like clorazepate are not recommended [12].
Imepitoin is a low-affinity partial agonist acting at the
benzodiazepine recognition site of the GABAA receptor
and was specifically developed for the treatment of canine
epilepsy [13]. Anticonvulsant activity and safety in dogs
were evaluated in several clinical and laboratory studies,
and on this basis imepitoin was licensed in the European
Union and in other countries to reduce the frequency of
generalized seizures due to idiopathic epilepsy in dogs
[14]. Imepitoin is now considered a first-line treatment
option in dogs with idiopathic epilepsy [15].
As cats react differently to some antiepileptic drugs
than dogs, an extrapolation from dog data to the feline
situation is not possible. Since other drugs acting at the
benzodiazepine recognition site on GABAA receptors,
appear to be efficacious in treating epileptic cats, we
hypothesized that imepitoin maintains the good anticon-
vulsant efficacy of benzodiazepines in cats, but as partial
low-affinity agonist will demonstrate the tolerability seen
in other species. The aim of these studies was to exam-
ine the tolerability of imepitoin in both healthy and
epileptic cats, and to obtain initial data on efficacy as a
pilot trial for further power analyses.
Methods
Experimental design
Three independent trials were conducted. Two tolerability
studies were performed in healthy laboratory cats and one
efficacy study was conducted in epileptic cats. In one of
the tolerability studies pharmacokinetics were also evalu-
ated. All three studies utilized different doses of imepitoin.
Study 1: In the first randomized, controlled, blinded
GLP (good laboratory practice) laboratory study, six cats
(3 male, 3 female) received orally 30 mg/kg imepitoin
twice daily over 30 days. Six untreated cats (3 male, 3
female) served as controls.
Study 2: The aim of the second, randomized, con-
trolled, blinded GLP laboratory study was to examine
safety in higher doses of 40 mg/kg and 80 mg/kg twice
daily, while placebo-treated animals served as control.
Each of the three parallel groups consisted of six cats (3
male, 3 female), and the treatment duration was 30 days.
Study 3: To evaluate tolerability under field conditions
in epileptic cats, a small, single-arm, open label, uncon-
trolled clinical pilot trial was performed in two centers.
In addition, efficacy parameters were assessed. Eight cats
suffering from idiopathic epilepsy (TIER II confidence
level [16]) were treated with 30 mg/kg imepitoin twice
daily for 8 weeks.
Medication
Imepitoin (Pexion®, Boehringer Ingelheim, Ingelheim,
Germany) was used in 100 mg or 400 mg tablets, each
divisible in two equal parts. For placebo, visually identi-
cal tablets without active ingredient were used. In the
laboratory studies, medication was provided twice daily,
approximately 12 h apart, using a tablet applicator (BUS-
TER; Jergen Kruuse A/S, Langeskov, Denmark). In the
clinical trial, owners provided tablets twice daily in the
morning and in the evening.
Laboratory trials in healthy cats
Intact domestic short hair cats (Liberty Research Inc.,
Waverly, NY, USA), aged one to 3 years, were kept
under a 12 h light/dark cycle at room temperature
(15 °C – 26 °C). Drinking water was offered ad libitum,
and food once daily. Food and water consumption was
monitored once daily during the study period and at base-
line. Environmental enrichment (toys, shelves, etc.) was
provided to all cats. In the first study (30 mg/kg), cats
were housed in groups (3 cats of same gender), while in
the second study (40/80 mg/kg) cats were kept individu-
ally for the study period.
Cats were observed daily for occurrence of adverse
events and general wellbeing, and a physical examination
was performed before treatment start, at day 7 (only in
40/80 mg/kg study), day 14 and day 30. This included a
general check of all body systems; body temperature
measurement, behavior and nervous system evaluation,
cardiovascular and respiratory assessment, and visual
examination of the eyes. Body weight was measured
once a week.
Blood samples were taken for hematology and clinical
chemistry 1 day before first dosing, at day 15 in study 1
(30 mg/kg study) and in all cats at day 30. An automated
complete blood count, including differential blood count
(ADVIA hematology system, Siemens Healthcare Diag-
nostics, Eschborn, Germany) and coagulation assessment
was performed. Clinical chemistry included a comprehen-
sive metabolic panel (study 1: HECKMAN Synchron CX7;
Heckman Coulter, Inc., Fullerton, USA or study 2: KONE-
LAB 30i, Thermo Fisher Scientific, Dreieich, Germany)
and additionally cholesterol, triglycerides, phosphate and
glutamate dehydrogenase (GLDH). Urine was analyzed
with test strips (study 1: Urispec® 9+ Leuko Plus; Henry
Schein Inc., Melville, USA or study 2: Combur 9® test,
Roche Diagnostics, Mannheim, Germany) and microscop-
ically 1 day before dosing, at day 15 (only study 1) and at
day 30. In the 30 mg/kg study, pharmacokinetics were
assessed at day 1, 15 and 29 collecting blood 0 h (i.e. prior
to treatment) and 30 min, 1, 3, 6 and 24 h after the first
treatment. To obtain at least 100 μL K3EDTA-plasma per
animal and sampling time, sufficient whole blood was
collected from the vena cephalica, saphena or jugularis.
Pharmacokinetic parameters were calculated with Phoenix
WinNonlin (Version 6.4; Pharsight/Certara, St. Louis MO
63101; USA) applying a noncompartmental analysis. To
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validate an adequate exposure to the test substance, in the
40 and 80 mg/kg study, blood was collected at day 1 and
28 at timepoints 0, 1, 3 and 24 h after first dosing.
Clinical trial
The study was conducted as a multicenter clinical
field trial, observing cats with newly diagnosed idio-
pathic epilepsy for 8 weeks of treatment with 30 mg/
kg imepitoin twice daily. If cats stayed on imepitoin
monotherapy after this 8 weeks observation period,
investigators attempted to follow the cat for as long
as possible.
Privately owned cats with epilepsy were included, if
they had a history of at least two generalized seizures
or focal seizures in the last 2 weeks prior to inclusion,
with at least two of the following signs: drooling, facial
twitching, tremor, rapid running, mydriasis, hypersali-
vation, disorientation, or impaired consciousness. Fur-
thermore, the minimum age had to be 9 months and a
signed Owner-Informed-Consent had to be obtained.
All cats had an MRI scan to rule out structural intra-
cranial lesions as cause for seizures (TIER II [16]).
Owners were asked to describe the seizures of their
cat, and the investigator graded them as focal or
generalized.
A cat was excluded, if it had been on oral antiepileptic
treatment for more than 3 consecutive days within the
last 6 months prior to inclusion, was treated with antiep-
ileptic drugs within the last 24 h prior to inclusion, was
known or suspected to be pregnant or lactating, had a
known or suspected concomitant disease that may be
accompanied by or result in neurological symptoms (e.g.
renal or liver failure, diabetes mellitus) which might
interfere with interpretation of the study results, or had
a life-threatening disease which may prevent completion
of the study (e.g. congestive heart failure).
Safety evaluation
At the end of the study, the investigator conducted a clin-
ical examination to determine the general health status of
the cat and asked the owners for their observations. In
addition, owners were asked to note observations of pos-
sible adverse events in the epilepsy seizure diary or to con-
tact the investigator immediately, if adverse events
occurred. All adverse events were recorded and classified
according to the Veterinary Dictionary for Drug Related
Affairs (VeDDRA).
Clinical efficacy assessment
During the study, owners were asked to observe their
cat for occurrence of seizures and to keep a record of
the occurrence of seizures (both focal and generalized)
in a patient diary. After 8 weeks, the investigator
reviewed the patient diary with the owner and recorded
the total number of seizures occurring during the study
period, the time to first seizure and the characteristics of
the seizures.
The primary measure of efficacy was the achievement
of seizure freedom [17]. Animals with at least 8 subse-
quent weeks of seizure freedom and no reported seizure
afterwards were counted as treatment success, at least
50% reduction in seizure frequency as partial success
and no sufficient improvement or lost to follow-up as
treatment failure. Seizures per individual treatment week
were recorded for each patient and plotted over time,
modifying a proposal for human epilepsy trials [18]. In
addition, monthly seizure frequency (MSF) before and
during treatment was calculated by dividing the number
of seizures by the number of weeks under observation
and multiplying the result by 4. The response ratio,
defined as the ratio [(T − B)/(T + B)] × 100 where
B = Baseline Seizure Rate and T = Treatment Seizure
Rate, was used to obtain a ‘symmetrized’ percent change
of seizure activity [19]. For all calculations, generalized
and partial seizures were taken into account.
Statistics
According to the nature of the data and the purpose of
the study, we applied appropriate descriptive statistics.
Data from the clinical trial were analyzed by two-sided
Wilcoxon matched-pairs signed rank test using GraphPad
Prism 6.05 (GraphPad Software, Inc., La Jolla, CA, USA;
conventionally p < 0.05 was considered significant).
Results
Imepitoin was well tolerated by healthy cats
No serious adverse events were observed in any of the
dose groups. Behavioural changes or sedation were not
noted during the course of the study. Repeated oral
administration of imepitoin to clinically healthy male
and female cats at doses of 30, 40 and 80 mg imepi-
toin/kg body weight twice daily for 30 days, led to
occasional emesis after at least 1 week of treatment.
Emesis was intermittently observed until test day 22
of treatment, possibly indicating a transient effect.
However, as emesis was more commonly observed in
verum groups, it is considered test-item related. Sali-
vation was the most frequent finding in the 40 and
80 mg/kg groups, while it was observed in only one
placebo cat.
At the highest doses (40 and 80 mg/kg), a slight reduc-
tion in food consumption was observed, especially at the
beginning of the study, with subsequently slightly lower
body weights compared to controls. No effect on body
weight or food consumption was observed in the pla-
cebo and 30 mg/kg group.
Urine analysis revealed no clinically evident effects of the
treatment. Haematology and clinical chemistry revealed no
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relevant changes. No changes in liver enzymes or other in-
dicators of hepatic malfunction were observed.
Pharmacokinetics of imepitoin in cats is similar to dogs
Pharmacokinetics was evaluated in the 30 mg/kg experi-
ment, and plasma samples were taken at 0, 0.5, 1, 3, 6
and 24 h post first treatment (second treatment 8-12 h
after first treatment). Therefore, no sampling points
were taken at the absorption and distribution phase of
the second dose and the pharmacokinetic evaluation was
based on the plasma concentration data of the first ab-
sorption/distribution phase (0, 0.5, 1, 3, 6 h post dose)
and the 24 h value (end of the second absorption/distri-
bution phase). No relevant gender effect was observed,
and accordingly male and female data (n = 3 per gender)
were combined for the pharmacokinetic analysis.
After 14 and 29 days of dosing a decrease in Cmax
(about 50%) and an about 60% reduction in exposure
(AUC) compared with day 1 data was observed (Table 1;
Fig. 1). The observed vomitus may have led to the fact
that individual animals had not received the full target
dose on days 14 and 29 which consequently resulted in a
lower systemic exposure and lower Cmax values and
may have been the reason for the observed differences.
Safety under field conditions
A total of 8 cats with newly diagnosed epilepsy with no
known underlying cause were recruited and received at
least a single dose of the appropriate drug treatment.
One cat was lost to follow-up, as neither the owner nor
the referring veterinarian provided further information.
Represented breeds were Domestic Shorthair (DSH,
n = 2) and European Shorthair (ESH, n = 6). Mean age
was 6.3 years (SD 5.8; Median 4; Range 1 to 15). Half of
the cats were female (n = 4), and all cats were neutered
(n = 8). Mean body weight at inclusion was 4.5 kg (SD
0.76 Range 3.0–5.0 kg). The mean initial dose was
27.92 mg/kg (SD 5.41; Median 30 mg/kg) twice daily.
Four cats had concomitant diseases, and one of these
cats had multiple diseases (hyperthyroidism, fibrosar-
coma, toothache and developed feline infectious peri-
tonitis after the observation period). In the other cats
the diseases were not considered to likely cause
neurological signs.
At least one adverse event was observed in five of
the seven evaluable cats. Most adverse events re-
ported were mild and occurred transiently or inter-
mittently. Lethargy was observed in two cases, which
resolved completely by lowering the dose to 20 mg/kg
twice daily and keeping the dose at this level. Two
cats showed emesis intermittently, and decreased ap-
petite was reported two times. In addition, ataxia,
polydipsia, increased appetite, increased salivation,
decreased appetite and decreased drinking were re-
ported one time each.
Efficacy under field conditions
In total, 4 out of 8 cats achieved seizure freedom at the
end of the study, while 1/8 experienced a partial thera-
peutic success, and 2/8 continued seizuring without
therapeutic success. One cat was lost to follow-up, and
accordingly 1/8 was considered undetermined and ac-
cordingly treatment failure (Fig. 2).
The monthly seizure frequency at baseline was
57.71 ± 73.77 seizures/month (mean ± SD; median 20;
range 2 to 200), which reduced significantly under treat-
ment to 19.43 ± 37.15 seizures/month (median 1.5;
range 0 to 100; p = 0.0313 in Wilcoxon matched-pairs
signed rank test compared to baseline). The response
ratio was −68.42 ± 38.52 (mean ± SD). Out of the four
cats which achieved seizure freedom at the end of the 8
week observation period, the mean reported time of
seizure freedom until they were lost to follow up in the
extended follow-up period was 16.4 weeks (SD 11.4;
range 8.0–30.4 weeks). In none of these cats further
seizures were reported until lost to follow-up.
Table 1 Pharmakokinetic parameters of imepitoin in healthy cats
Day
1 14 29
Cmax AUClast Tmax Cmax AUClast Tmax Cmax AUClast Tmax
Dose 30 mg/kg 9990 39,640 3.0 2940 11,720 1.0 1590 6932 3.0
5180 35,870 1.0 1840 7615 1.0 5600 47,560 1.0
5980 46,780 3.0 1910 9726 0.5 934 4242 0.5
7220 35,030 3.0 4380 9883 1.0 1400 4115 0.5
6830 47,970 1.0 6540 22,620 1.0 6300 26,190 1.0
5880 35,790 3.0 3240 15,850 1.0 7500 20,800 1.0
N 6 6 6 6 6 6 6 6 6
Mean 6850 40,200 2.3 3480 12,900 0.92 3890 18,300 1.2
SD 1700 5810 1.0 1770 5510 0.20 2900 17,000 0.93
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One cat had 3 seizures during the first 4 weeks of treat-
ment, and had no further seizures for the next 5 weeks.
As it was lost to follow-up then and did not meet 8 weeks
of seizure freedom, it was classified partial success.
In the two cats that continued seizuring without thera-
peutic success, one cat had continuous seizure activity
during the first 2 weeks of imepitoin treatment, so pheno-
barbital (1 mg/kg twice daily, serum level 34.5 μmol/ml)
was added to imepitoin in the third week after inclusion.
Seizure frequency decreased during the following weeks,
and from week 7 after inclusion onwards, no further
seizures were observed. Seizure freedom remained for
4 weeks. Afterwards no information was available.
Following an initial improvement in the first week,
the other cat experienced highly frequent focal seizures
in the second week of imepitoin treatment. Subse-
quently, the owners wished to change treatment, and
levetiracetam (20 mg/kg 3 times daily) was added to
imepitoin treatment. A slight improvement in seizure
frequency was observed, however even with increasing
the dose of levetiracetam (to 30 mg/kg 3 times daily),
sufficient seizure control was not achieved. In week six
after inclusion, imepitoin was gradually replaced by
phenobarbital. After switching to phenobarbital and
levetiracetam, no information on the further course of
disease was available.
Fig. 1 a Mean Imepitoin plasma concentration over time on day 1, 14, and 29 (linear scale) b Logarithmic scale of mean Imepitoin plasma
concentration over time on day 1, 14, and 29
Fig. 2 a Seizures per treatment week (each line represents one individual patient). Two cats had an identical course of disease (1 seizure/week at
baseline). b 4 / 8 animals were classified as seizure-free and 1 / 8 had a partial therapeutic success with decreasing frequency of seizures over
time, while 2 / 8 continued seizuring without therapeutic success and one was considered undetermined due to lost to follow-up
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Discussion
This is the first report demonstrating the safety and first
exploratory efficacy data of imepitoin in cats with epi-
lepsy, and it describes one of the rare prospective clinical
trials in feline epilepsy.
Usually, laboratory studies evaluating the safety of vet-
erinary drug candidates end with a complete necropsy.
In contrast, new drugs for humans are tested during ini-
tial Phase I clinical trials in a small number of healthy
volunteers in escalating doses to analyze safety, tolerance
and pharmacokinetics of the given drug. Afterwards,
during Phase II, the drug is given for the first time to pa-
tients to analyze the therapeutic effect of the dose, and
then in Phase III the efficacy of the new drug is evalu-
ated in clinical practices. Based on the extensive toxico-
logical data already available for imepitoin [13], we more
or less followed the first two phases of human new drug
development.
In the first phase, we applied escalating doses of
30 mg/kg, 40 mg/kg and 80 mg/kg imepitoin twice daily
to different groups of healthy cats. No serious adverse
events were observed in any of the dose groups. In the
imepitoin treated groups, emesis was observed in some
animals temporarily and intermittently mainly in the
second and third weeks of treatment. No signs of sed-
ation were observed. All hepatic parameters assessed
revealed no influence of imepitoin on the liver, however
no pathology was performed due to the aforementioned
reasons. We hypothesize that emesis might be reduced
by suitable application protocols like reduction of stress,
application with food, or use of antiemetics. However
this remains to be examined in dedicated future studies.
In the second phase, the good safety profile of imepi-
toin in healthy cats was confirmed under field conditions
in epileptic cats, and - in contrast to benzodiazepines
or other antiepileptics [8] - we did not observe “cat-
specific” reactions to imepitoin compared to other
species. The pharmacokinetic profile appeared to be
similar to dogs [20]. It appears likely, that vomiting
accounted for the observed decrease in exposure over
the course of the study.
In general, the prognosis of epilepsy of unknown cause
in cats is regarded as good if appropriately treated [21].
In this prospective clinical trial, seizure freedom was
achieved in 50% of cats, however the follow-up period
was relatively short for a definitive conclusion on long-
term outcome [17]. Clinical experiences with phenobar-
bital resulted in seizure freedom in about 40–50% of
patients treated [22–24]. A similar rate was reported for
bromide, however associated with more adverse events
including idiosyncratic allergic pneumonitis [25]. The
only available data on levetiracetam as add-on therapy
to phenobarbital reported 25–30% seizure freedom [26].
Our study demonstrated a rate of seizure freedom with
imepitoin treatment similar to that previously reported
for phenobarbital in cats. Evaluating individual seizure
incidences per week revealed that seizures may not dis-
appear immediately, but appear to decrease gradually
during the first weeks of treatment.
Despite all efforts to include only cats with idiopathic
epilepsy, one of the cats included in the field efficacy
study suffered from Feline Infectious Peritonitis, which
may be a cause of seizures [27]. This cat responded well
to antiepileptic treatment with imepitoin.
Conclusions
To date there are no licensed treatments for feline
epilepsy and no well-controlled clinical studies on the
efficacy or safety of antiepileptic drugs in cats. Based on
the data presented, imepitoin appears to be a potential
candidate for treatment of epilepsy in cats. In all three
studies treatment with imepitoin was well tolerated in
cats. The results suggest a potential therapeutic effect,
however the main limitation of the clinical trial is the
small sample size, and accordingly no definitive conclu-
sions on efficacy can be made. Further larger studies are
needed to confirm the results of this initial pilot study.
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